Skip to main content

Advertisement

SpringerLink
Log in

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS) for Colorectal Cancer: Potential for Individualized Care, Review of Current Treatment Trends, Recent Advancements, and a Look into the Future

  • Basic Science Foundations in Colorectal Cancer (S Umar, Section Editor)
  • Published:
Current Colorectal Cancer Reports

Abstract

Purpose of Review

Peritoneal metastases (PM) secondary to colorectal cancer is associated with a poor prognosis. However, cytoreductive surgery with hyperthermia intraperitoneal chemotherapy (CRS/HIPEC) has risen to a more accepted roll in the treatment of peritoneal metastatic disease for various cancers; colorectal cancer is no exception. This review aims to discuss the recent updates and findings for treatment of peritoneal disease secondary to colorectal cancer, especially with respect to individualized patient factors that affect outcomes.

Recent Findings

There are many new studies showing the validity of cytoreductive surgery CRS/HIPEC in a select group of patients with PM. Many studies show that lower peritoneal cancer index score, use of various chemotherapeutic regimens, histology, preoperative health status, adequate nutrition, and other factors all benefit survival/treatment of this unique patient group.

Summary

Current evidence supports an aggressive multidisciplinary approach to peritoneal disease secondary to colorectal cancer. Standardized treatment practice, highly selective patient criteria, low PCI score, and early recognition of patients at risk for PM show survival benefits and better outcomes for patients with a disease process that was once only treated with palliative interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies. Cancer. 2000;88(2):358–63.

    Article  PubMed  CAS  Google Scholar 

  2. Baumgartner JM, Tobin L, Heavey SF, Kelly KJ, Roeland EJ, Lowy AM. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22(5):1716–21.

    Article  PubMed  Google Scholar 

  3. Kuijpers AM, Mehta AM, Boot H, van Leerdam ME, Hauptmann M, Aalbers AG, et al. Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Oncol. 2014;25(4):864–9.

    Article  PubMed  CAS  Google Scholar 

  4. Rivard JD, McConnell YJ, Temple WJ, Mack LA. Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: are we excluding patients who may benefit? J Surg Oncol. 2014;109(2):104–9.

    Article  PubMed  Google Scholar 

  5. Waite K, Youssef H. The role of neoadjuvant and adjuvant systemic chemotherapy with cytoreductive surgery and heated intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review. Ann Surg Oncol. 2017;24(3):705–20.

    Article  PubMed  Google Scholar 

  6. van Eden WJ, Kok NF, Jozwiak K, Lahaye ML, Beets GL, van Leerdam ME, et al. Timing of systemic chemotherapy in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Dis Colon Rectum. 2017;60(5):477–87.

    Article  PubMed  Google Scholar 

  7. Devilee RA, Simkens GA, van Oudheusden TR, Rutten HJ, Creemers GJ, Ten Tije AJ, et al. Increased survival of patients with synchronous colorectal peritoneal metastases receiving preoperative chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2841–8.

    Article  PubMed  CAS  Google Scholar 

  8. Ceelen W, Van Nieuwenhove Y, Putte DV, Pattyn P. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ann Surg Oncol. 2014;21(9):3023–8.

    Article  PubMed  Google Scholar 

  9. Rovers KP, Simkens GA, Punt CJ, van Dieren S, Tanis PJ, de Hingh IH. Perioperative systemic therapy for resectable colorectal peritoneal metastases: sufficient evidence for its widespread use? A critical systematic review. Crit Rev Oncol Hematol. 2017;114:53–62.

    Article  PubMed  Google Scholar 

  10. Eveno C, Passot G, Goere D, Soyer P, Gayat E, Glehen O, et al. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2014;21(6):1792–800.

    Article  PubMed  Google Scholar 

  11. Desolneux G, Maziere C, Vara J, Brouste V, Fonck M, Bechade D, et al. Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLoS One. 2015;10(3):e0122816.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Bhandare M, Patil P, Pai V, Bhamre R, Engineer R, Ostwal V, et al. Peritoneal carcinomatosis in colorectal cancers - management perspective needs a change. Clin Colorectal Cancer. 2017;16(2):e1–6.

    Article  PubMed  Google Scholar 

  13. Piso P, Stierstorfer K, Gerken M, Klinkhammer-Schalke M. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer. Int J Color Dis. 2018;33:1559–67.

    Article  Google Scholar 

  14. Riss S, Mohamed F, Dayal S, Cecil T, Stift A, Bachleitner-Hofmann T, et al. Peritoneal metastases from colorectal cancer: patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2013;39(9):931–7.

    Article  PubMed  CAS  Google Scholar 

  15. Elias D, Mariani A, Cloutier AS, Blot F, Goere D, Dumont F, et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol. 2014;40(11):1467–73.

    Article  PubMed  CAS  Google Scholar 

  16. Goere D, Souadka A, Faron M, Cloutier AS, Viana B, Honore C, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22(9):2958–64.

    Article  PubMed  Google Scholar 

  17. Huang Y, Alzahrani NA, Alzahrani SE, Zhao J, Liauw W, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly. World J Surg Oncol. 2015;13:262.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kwakman R, Schrama AM, van Olmen JP, Otten RH, de Lange-de Klerk ES, de Cuba EM, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg. 2016;263(6):1102–11.

    Article  PubMed  Google Scholar 

  19. Ng JL, Ong WS, Chia CS, Tan GH, Soo KC, Teo MC. Prognostic relevance of the peritoneal surface disease severity score compared to the peritoneal cancer index for colorectal peritoneal carcinomatosis. Int J Surg Oncol. 2016;2016:2495131.

    PubMed  PubMed Central  Google Scholar 

  20. Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. TheScientificWorldJOURNAL. 2013;2013:978394.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Berger Y, Aycart S, Mandeli JP, Heskel M, Sarpel U, Labow DM. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: outcomes from a single tertiary center. Surg Oncol. 2015;24(3):264–9.

    Article  PubMed  Google Scholar 

  22. Faron M, Macovei R, Goere D, Honore C, Benhaim L, Elias D. Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Ann Surg Oncol. 2016;23(1):114–9.

    Article  PubMed  Google Scholar 

  23. Guerrero W, Munene G, Dickson PV, Stiles ZE, Mays J, Davidoff AM, et al. Outcome and factors associated with aborted cytoreduction for peritoneal carcinomatosis. J Gastrointest Oncol. 2018;9(4):664–73.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Simkens GA, Razenberg LG, Lemmens VE, Rutten HJ, Creemers GJ, de Hingh IH. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases. Eur J Surg Oncol. 2016;42(6):794–800.

    Article  PubMed  CAS  Google Scholar 

  25. Massalou D, Benizri E, Chevallier A, Duranton-Tanneur V, Pedeutour F, Benchimol D, et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017;213(2):377–87.

    Article  PubMed  Google Scholar 

  26. van Oudheusden TR, Braam HJ, Nienhuijs SW, Wiezer MJ, van Ramshorst B, Luyer P, et al. Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology. J Surg Oncol. 2015;111(2):237–42.

    Article  PubMed  Google Scholar 

  27. • Enblad M, Ghanipour L, Cashin PH. Prognostic scores for colorectal cancer with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2018:1–6. Compared various scoring systems to determine the most useful for individualized patient selection. It suggested cutoff points to allow clinicians to determine who would benefit from attempted HIPEC and for whom the risk would not be worth the benefit.

  28. Elias D, Faron M, Goere D, Dumont F, Honore C, Boige V, et al. A simple tumor load-based nomogram for surgery in patients with colorectal liver and peritoneal metastases. Ann Surg Oncol. 2014;21(6):2052–8.

    Article  PubMed  Google Scholar 

  29. Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) multiinstitution evaluation of the peritoneal surface disease severity score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis. Ann Surg Oncol. 2014;21(13):4195–201.

    Article  PubMed  Google Scholar 

  30. Kozman MA, Fisher OM, Rebolledo BJ, Parikh R, Valle SJ, Arrowaili A, et al. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: a retrospective cohort study. J Surg Oncol. 2018;117(4):725–36.

    Article  PubMed  CAS  Google Scholar 

  31. Yoon W, Alame A, Berri R. Peritoneal surface disease severity score as a predictor of resectability in the treatment of peritoneal surface malignancies. Am J Surg. 2014;207(3):403–7 discussion 6-7.

    Article  PubMed  Google Scholar 

  32. Simkens GA, Rovers KP, Nienhuijs SW, de Hingh IH. Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer. Cancer Manag Res. 2017;9:259–66.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Robella M, Vaira M, Marsanic P, Mellano A, Cinquegrana A, Sottile A, et al. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and HIPEC: preliminary results in highly selected patients. Minerva Chir. 2013;68(6):551–8.

    PubMed  CAS  Google Scholar 

  34. Nikolic S, Dzodic R, Zegarac M, Djurisic I, Gavrilovic D, Vojinovic V, et al. Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience. J BUON. 2014;19(1):66–74.

    PubMed  Google Scholar 

  35. Cashin PH, Graf W, Nygren P, Mahteme H. Comparison of prognostic scores for patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20(13):4183–9.

    Article  PubMed  Google Scholar 

  36. Simkens GA, van Oudheusden TR, Nieboer D, Steyerberg EW, Rutten HJ, Luyer MD, et al. Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC. Ann Surg Oncol. 2016;23(13):4214–21.

    Article  PubMed  Google Scholar 

  37. Abreu de Carvalho LF, Scuderi V, Maes H, Cupo P, Geerts B, Van Bockstal M, et al. Simultaneous parenchyma-preserving liver resection, cytoreductive surgery and intraperitoneal chemotherapy for stage IV colorectal cancer. Acta Chir Belg. 2015;115(4):261–7.

    Article  PubMed  CAS  Google Scholar 

  38. Alzahrani N, Ung L, Valle SJ, Liauw W, Morris DL. Synchronous liver resection with cytoreductive surgery for the treatment of liver and peritoneal metastases from colon cancer: results from an Australian centre. ANZ J Surg. 2017;87(11):E167–e72.

    Article  PubMed  Google Scholar 

  39. Baratti D, Kusamura S, Iusco D, Cotsoglou C, Guaglio M, Battaglia L, et al. Should a history of extraperitoneal disease be a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer peritoneal metastases? Dis Colon Rectum. 2018;61(9):1026–34.

    Article  PubMed  Google Scholar 

  40. Lorimier G, Linot B, Paillocher N, Dupoiron D, Verriele V, Wernert R, et al. Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer. Eur J Surg Oncol. 2017;43(1):150–8.

    Article  PubMed  CAS  Google Scholar 

  41. Navez J, Remue C, Leonard D, Bachmann R, Kartheuser A, Hubert C, et al. Surgical treatment of colorectal cancer with peritoneal and liver metastases using combined liver and cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: report from a single-centre experience. Ann Surg Oncol. 2016;23(Suppl 5):666–73.

    Article  PubMed  Google Scholar 

  42. Saxena A, Valle SJ, Liauw W, Morris DL. Limited synchronous hepatic resection does not compromise peri-operative outcomes or survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2017;115(4):417–24.

    Article  PubMed  Google Scholar 

  43. Cloyd JM, Abdel-Misih S, Hays J, Dillhoff ME, Pawlik TM, Schmidt C. Impact of synchronous liver resection on the perioperative outcomes of patients undergoing CRS-HIPEC. J Gastrointest Surg. 2018;22(9):1576–84.

    Article  PubMed  Google Scholar 

  44. Delhorme JB, Dupont-Kazma L, Addeo P, Lefebvre F, Triki E, Romain B, et al. Peritoneal carcinomatosis with synchronous liver metastases from colorectal cancer: who will benefit from complete cytoreductive surgery? Int J Surg. 2016;25:98–105.

    Article  PubMed  Google Scholar 

  45. Downs-Canner S, Shuai Y, Ramalingam L, Pingpank JF, Holtzman MP, Zeh HJ, et al. Safety and efficacy of combined resection of colorectal peritoneal and liver metastases. J Surg Res. 2017;219:194–201.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Votanopoulos KI, Swett K, Blackham AU, Ihemelandu C, Shen P, Stewart JH, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer. Ann Surg Oncol. 2013;20(4):1088–92.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Simkens GA, van Oudheusden TR, Braam HJ, Wiezer MJ, Nienhuijs SW, Rutten HJ, et al. Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study. J Surg Oncol. 2016;113(5):548–53.

    Article  PubMed  Google Scholar 

  48. Tonello M, Ortega-Perez G, Alonso-Casado O, Torres-Mesa P, Guinez G, Gonzalez-Moreno S. Peritoneal carcinomatosis arising from rectal or colonic adenocarcinoma treated with cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC): two different diseases. Clin Transl Oncol. 2018;20:1268–73.

    Article  PubMed  CAS  Google Scholar 

  49. Virzi S, Iusco D, Baratti D, Bonomi S, Grassi A, Kusamura S, et al. Pilot study of adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases. Tumori. 2013;99(5):589–95.

    Article  PubMed  Google Scholar 

  50. • Baratti D, Kusamura S, Iusco D, Gimondi S, Pietrantonio F, Milione M, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of primary curative surgery in patients with colorectal cancer at high risk for metachronous peritoneal metastases. Ann Surg Oncol. 2017;24(1):167–75 Data shows that it may be best to preform HIPEC at discovery of peritoneal metastasis rather than at a later date. This paper points towards earlier treatment of patients with peritoneal disease and improved outcomes in survival.

    Article  PubMed  Google Scholar 

  51. Cloutier AS, Faron M, Honore C, Goere D, Dumont F, Vittadello F, et al. Second-look surgery plus HIPEC for patients with colorectal cancer at high risk of peritoneal carcinomatosis: should we resect the initial anastomosis? An observational study. Eur J Surg Oncol. 2015;41(8):1068–73.

    Article  PubMed  CAS  Google Scholar 

  52. Delhorme JB, Triki E, Romain B, Meyer N, Rohr S, Brigand C. Routine second-look after surgical treatment of colonic peritoneal carcinomatosis. J Visc Surg. 2015;152(3):149–54.

    Article  PubMed  CAS  Google Scholar 

  53. Klaver YL, Chua TC, Verwaal VJ, de Hingh IH, Morris DL. Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction. J Surg Oncol. 2013;107(6):585–90.

    Article  PubMed  Google Scholar 

  54. Sammartino P, Biacchi D, Cornali T, Cardi M, Accarpio F, Impagnatiello A, et al. Proactive management for gastric, colorectal and appendiceal malignancies: preventing peritoneal metastases with hyperthermic intraperitoneal chemotherapy (HIPEC). Indian J Surg Oncol. 2016;7(2):215–24.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Klaver CE, Musters GD, Bemelman WA, Punt CJ, Verwaal VJ, Dijkgraaf MG, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15:428.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21(5):1501–5.

    Article  PubMed  CAS  Google Scholar 

  57. Kitayama J. Intraperitoneal chemotherapy against peritoneal carcinomatosis: current status and future perspective. Surg Oncol. 2014;23(2):99–106.

    Article  PubMed  Google Scholar 

  58. Rodriguez Silva C, Moreno Ruiz FJ, Bellido Estevez I, Carrasco Campos J, Titos Garcia A, Ruiz Lopez M, et al. Are there intra-operative hemodynamic differences between the Coliseum and closed HIPEC techniques in the treatment of peritoneal metastasis? A retrospective cohort study. World J Surg Oncol. 2017;15(1):51.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Lotti M, Giulii Capponi M, Campanati L, Poiasina E, Ansaloni L, Poletti E, et al. The onset of intra-abdominal adhesions during closed-abdomen hyperthermic intraperitoneal chemotherapy. J Laparoendosc Adv Surg Techn A. 2016;26(12):997–1002.

    Article  Google Scholar 

  60. Lam JY, McConnell YJ, Rivard JD, Temple WJ, Mack LA. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Am J Surg. 2015;210(3):424–30.

    Article  PubMed  Google Scholar 

  61. McConnell YJ, Mack LA, Francis WP, Ho T, Temple WJ. HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol. 2013;107(6):591–6.

    Article  PubMed  CAS  Google Scholar 

  62. Gervais MK, Dube P, McConnell Y, Drolet P, Mitchell A, Sideris L. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer. J Surg Oncol. 2013;108(7):438–43.

    Article  PubMed  CAS  Google Scholar 

  63. Mehta AM, Huitema AD, Burger JW, Brandt-Kerkhof AR, van den Heuvel SF, Verwaal VJ. Standard clinical protocol for bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC): systemic leucovorin, 5-fluorouracil, and heated intraperitoneal oxaliplatin in a chloride-containing carrier solution. Ann Surg Oncol. 2017;24(4):990–7.

    Article  PubMed  Google Scholar 

  64. Glockzin G, von Breitenbuch P, Schlitt HJ, Piso P. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis. J Surg Oncol. 2013;107(6):574–8.

    Article  PubMed  CAS  Google Scholar 

  65. van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2018;44(2):220–7.

    Article  PubMed  Google Scholar 

  66. Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res. 2013;179(1):e133–9.

    Article  PubMed  CAS  Google Scholar 

  67. Glockzin G, Gerken M, Lang SA, Klinkhammer-Schalke M, Piso P, Schlitt HJ. Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis. BMC Cancer. 2014;14:807.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Hompes D, D'Hoore A, Wolthuis A, Fieuws S, Mirck B, Bruin S, et al. The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol. 2014;109(6):527–32.

    Article  PubMed  CAS  Google Scholar 

  69. Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110(7):779–85.

    Article  PubMed  CAS  Google Scholar 

  70. Huang CQ, Min Y, Wang SY, Yang XJ, Liu Y, Xiong B, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget. 2017;8(33):55657–83.

    PubMed  PubMed Central  Google Scholar 

  71. Glockzin G, Zeman F, Croner RS, Konigsrainer A, Pelz J, Strohlein MA, et al. Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: results of the prospective multicenter phase 2 COMBATAC trial. Clin Colorectal Cancer. 2018;17:285–96.

    Article  PubMed  Google Scholar 

  72. Bouhadjari N, Gabato W, Calabrese D, Msika S, Keita H. Hyperthermic intraperitoneal chemotherapy with cisplatin: amifostine prevents acute severe renal impairment. Eur J Surg Oncol. 2016;42(2):219–23.

    Article  PubMed  CAS  Google Scholar 

  73. Kemmel V, Mercoli HA, Meyer N, Brumaru D, Romain B, Lessinger JM, et al. Mitomycin C pharmacokinetics as predictor of severe neutropenia in hyperthermic intraperitoneal therapy. Ann Surg Oncol. 2015;22(Suppl 3):S873–9.

    Article  PubMed  Google Scholar 

  74. Chemama S, Bayar MA, Lanoy E, Ammari S, Stoclin A, Goere D, et al. Sarcopenia is associated with chemotherapy toxicity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol. 2016;23(12):3891–8.

    Article  PubMed  Google Scholar 

  75. Barabino G, Klein JP, Porcheron J, Grichine A, Coll JL, Cottier M. Intraoperative near-infrared fluorescence imaging using indocyanine green in colorectal carcinomatosis surgery: proof of concept. Eur J Surg Oncol. 2016;42(12):1931–7.

    Article  PubMed  CAS  Google Scholar 

  76. Liberale G, Vankerckhove S, Caldon MG, Ahmed B, Moreau M, Nakadi IE, et al. Fluorescence imaging after indocyanine green injection for detection of peritoneal metastases in patients undergoing cytoreductive surgery for peritoneal carcinomatosis from colorectal cancer: a pilot study. Ann Surg. 2016;264(6):1110–5.

    Article  PubMed  Google Scholar 

  77. Lieto E, Auricchio A, Cardella F, Mabilia A, Basile N, Castellano P, et al. Fluorescence-guided surgery in the combined treatment of peritoneal carcinomatosis from colorectal cancer: preliminary results and considerations. World J Surg. 2018;42(4):1154–60.

    Article  PubMed  Google Scholar 

  78. Harlaar NJ, Koller M, de Jongh SJ, van Leeuwen BL, Hemmer PH, Kruijff S, et al. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. Lancet Gastroenterol Hepatol. 2016;1(4):283–90.

    Article  PubMed  Google Scholar 

  79. Chan CH, Liesenfeld LF, Ferreiro-Neira I, Cusack JC Jr. Preclinical evaluation of cathepsin-based fluorescent imaging system for cytoreductive surgery. Ann Surg Oncol. 2017;24(4):931–8.

    Article  PubMed  Google Scholar 

  80. De Vos N, Goethals I, Ceelen W. Clinical value of (18)F-FDG- PET-CT in the preoperative staging of peritoneal carcinomatosis from colorectal origin. Acta Chir Belg. 2014;114(6):370–5.

    Article  PubMed  Google Scholar 

  81. Audollent R, Eveno C, Dohan A, Sarda L, Jouvin I, Soyer P, et al. Pitfalls and mimickers on (18)F-FDG-PET/CT in peritoneal carcinomatosis from colorectal cancer: an analysis from 37 patients. J Visc Surg. 2015;152(5):285–91.

    Article  PubMed  CAS  Google Scholar 

  82. Liberale G, Lecocq C, Garcia C, Muylle K, Covas A, Deleporte A, et al. Accuracy of FDG-PET/CT in colorectal peritoneal carcinomatosis: potential tool for evaluation of chemotherapeutic response. Anticancer Res. 2017;37(2):929–34.

    Article  PubMed  CAS  Google Scholar 

  83. •• Roy P, Canet-Jourdan C, Annereau M, Zajac O, Gelli M, Broutin S, et al. Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: preclinical models to improve HIPEC. Int J Pharm. 2017;531(1):143–52 Validated the use of organoids for the testing of different HIPEC drugs to use for peritoneal carcinomatosis due to colorectal cancer. This would have profound implications for developing appropriate chemotherapy regimens, both in terms of composition of drugs selected, temperature used, and duration of therapy.

    Article  PubMed  CAS  Google Scholar 

  84. Sluiter N, de Cuba E, Kwakman R, Kazemier G, Meijer G, Te Velde EA. Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options. Clin Exp Metastasis. 2016;33(5):401–16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Sluiter NR, de Cuba EM, Kwakman R, Meijerink WJ, Delis-van Diemen PM, Coupe VM, et al. Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Clin Exp Metastasis. 2016;33(4):297–307.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. de Cuba EM, de Hingh IH, Sluiter NR, Kwakman R, Coupe VM, Belien JA, et al. Angiogenesis-related markers and prognosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. Ann Surg Oncol. 2016;23(5):1601–8.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Kwakman R, de Cuba EM, de Winter JP, de Hingh IH, Delis-van Diemen PM, Tijssen M, et al. Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival. Br J Cancer. 2015;112(5):851–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Melero JT, Ortega FG, Gonzalez AM, Carmona-Saez P, Garcia Puche JL, Sugarbaker PH, et al. Prognostic factor analysis of circulating tumor cells in peripheral blood of patients with peritoneal carcinomatosis of colon cancer origin treated with cytoreductive surgery plus an intraoperative hyperthermic intraperitoneal chemotherapy procedure (CRS + HIPEC). Surgery. 2016;159(3):728–35.

    Article  PubMed  Google Scholar 

  89. Enblad M, Birgisson H, Wanders A, Skoldberg F, Ghanipour L, Graf W. Importance of absent neoplastic epithelium in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(4):1149–56.

    Article  PubMed  Google Scholar 

  90. • Froysnes IS, Andersson Y, Larsen SG, Davidson B, Oien JT, Olsen KH, et al. Novel treatment with intraperitoneal MOC31PE immunotoxin in colorectal peritoneal metastasis: results from the ImmunoPeCa phase 1 trial. Ann Surg Oncol. 2017;24(7):1916–22 An important article that shows what the future holds for individualized patient care and theraputic options to treat peritoneal disease from colorectal cancer.

    Article  PubMed  Google Scholar 

  91. Chia CS, Tan WJ, Wong JF, Tan GH, Lim C, Wang W, et al. Quality of life in patients with peritoneal surface malignancies after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2014;40(8):909–16.

    Article  PubMed  CAS  Google Scholar 

  92. Passot G, Bakrin N, Roux AS, Vaudoyer D, Gilly FN, Glehen O, et al. Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. Eur J Surg Oncol. 2014;40(5):529–35.

    Article  PubMed  CAS  Google Scholar 

  93. Ford J, Hanna M, Boston A, Berri R. Life after hyperthermic intraperitoneal chemotherapy; measuring quality of life and performance status after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Am J Surg. 2016;211(3):546–50.

    Article  PubMed  Google Scholar 

  94. Tsilimparis N, Bockelmann C, Raue W, Menenakos C, Perez S, Rau B, et al. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol. 2013;20(1):226–32.

    Article  PubMed  Google Scholar 

  95. Chia CS, Tan GH, Lim C, Soo KC, Teo MC. Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2905–13.

    Article  PubMed  Google Scholar 

  96. Dineen SP, Robinson KA, Roland CL, Beaty KA, Rafeeq S, Mansfield PF, et al. Feeding tube placement during cytoreductive surgery and heated intraperitoneal chemotherapy does not improve postoperative nutrition and is associated with longer length of stay and higher readmission rates. J Surg Res. 2016;200(1):158–63.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA

    Craig Follette, Sean Liebscher & Tyler Mouw

  2. Oncologic Surgery Division, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA

    Mazin Al-Kasspooles

Authors
  1. Craig Follette
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sean Liebscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tyler Mouw
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mazin Al-Kasspooles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mazin Al-Kasspooles.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

Section Editor: S Umar

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Basic Science Foundations in Colorectal Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Follette, C., Liebscher, S., Mouw, T. et al. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS) for Colorectal Cancer: Potential for Individualized Care, Review of Current Treatment Trends, Recent Advancements, and a Look into the Future. Curr Colorectal Cancer Rep 15, 36–44 (2019). https://doi.org/10.1007/s11888-019-00427-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-019-00427-1

Keywords

Search

Navigation